Company news
Korro Bio, Inc. news in 2021
Korro Bio, Inc.'s news releases, calls and decks from 2021, newest first.
Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
December 8, 2021
Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results
November 14, 2021
Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis
November 8, 2021
Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program
October 26, 2021
Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint
October 20, 2021
Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points
September 21, 2021
Frequency Therapeutics to Present at Upcoming Investor Conferences
September 7, 2021
Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results
August 11, 2021
Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences
May 24, 2021
Frequency Therapeutics Provides Statement of Support for the Hearing Loss Association of America’s Externally-Led Patient-Focused Drug Development Meeting to Address Sensorineural Hearing Loss
May 19, 2021
Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results
May 12, 2021
Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science
April 12, 2021
Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
April 8, 2021
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2020 Financial Results
March 28, 2021
Frequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose Regimen
March 22, 2021
Frequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322
February 21, 2021
Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning
February 7, 2021
Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer
January 18, 2021
Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021